| Saturday, November 3 |
| 8:00 am - 8:45 am |
Saturday Keynote Address
Adoptive T Cell Therapy: Grand Challenges and Opportunities
 Carl H. June, MD - University of Pennsylvania |
| 8:45 am - 11:30 am |
Plenary Session: Immuoregulation and Mediated Tolerance
Co-Chairs:
Vincenzo Bronte, MD - Istituto Oncologico Veneto
F. Stephen Hodi, MD - Dana-Farber Cancer Institute
|
| 8:45 am - 9:00 am |
Elevated Foxp3+CD4+CD25+ Regulatory T Cells in Tumor-Bearing
Mice Suppress T-Cell Priming, Effector-Cell Function and Anti-Tumor Immunity
Zuqiang Liu, PhD - University of Pittsburgh School of Medicine |
| 9:00 am - 9:30 am |
Manipulating Immune Tolerance Unmasks the Latent Immune-Modulating Potential of Cancer Therapeutics
Leisha A. Emens, MD, PhD - Johns Hopkins University |
| 9:30 am - 9:45 am |
Different Flavors of Regulatory T-Cell (Treg) Subsets in
Patients with Cancer and Their Role in Tumor Escape
Christoph Bergmann, MD, PhD - University of Duisburg-Essen |
| 9:45 am - 10:00 am |
Ex Vivo Depletion of CD81+ Tumor-Induced Regulatory T Cells Restores Priming of Tumor-Specific Effector T Cells Generated in
Reconstituted, Lymphopenic Hosts
Christian Poehlein, MD - Earle A. Chiles Research Institute |
| 10:00 am - 10:15 am |
Foxp3 is Expressed by Tumor Cells, Virally Transformed B Cells, and Germ Cells
Weisan Chen, PhD - Ludwig Institute for Cancer Research |
| 10:45 am - 11:00 am |
TGF-Beta Signaling Plays a Crucial Role for De Novo Induction of
Adaptive Regulatory T Cells but Is Not Required for the
Immunosuppressive Effect Mediated by Tumor-Induced Regulatory T Cells
Ulf Petrausch, MD - Earle A. Chiles Research Institute |
| 11:00 am - 11:30 am |
Myeloid-Derived Suppressor Cells in Cancer
Vincenzo Bronte, MD - Istituto Oncologico Veneto |
| 1:30 pm - 3:00 pm |
Concurrent Session I: Tumor Recognition / Immune Evasion
Co-Chairs:
Paul F. Robbins, PhD - National Cancer Institute
Thomas Spies, PhD - Fred Hutchinson Cancer Research Center
|
| 1:30 pm - 2:00 pm |
Adoptive Immunotherapy of Malignancies with Gene Modified, EBV-Specific, Cytotoxic T-Cell Lines
Malcolm K. Brenner, MD, PhD - Baylor College of Medicine |
| 2:00 pm - 2:30 pm |
Therapeutically Accessible Molecules That Regulate the Regulators
Drew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine |
| 2:30 pm - 2:45 pm |
Tumor-Derived Macrophage Migration Inhibitory Factor (MIF)
Inhibits Immune Reactivity to Neuroblastoma In Vivo
Bryon D. Johnson, PhD - Medical College of Wisconsin |
| 2:45 pm - 3:00 pm |
5-aza-2’- Deoxycytidine Treatment Increases Expression of Tumor
Associated Antigens in Human Melanoma
Timothy Haggerty, PhD - CytoCure LLC |
| 1:30 pm - 3:00 pm |
Concurrent Session II: New Agents
Co-Chairs:
Elizabeth A. Repasky, PhD - Rosewell Park Cancer Institute
Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
|
| 1:30 pm - 1:45 pm |
PTTG-1: An Immunological Target for Multiple Myeloma
Maurizio Chiriva, PhD - Texas Tech University Health Sciences Center |
| 1:45 pm - 2:00 pm |
A Phase II Study of Tremelimumab (CP-675,206), an Anti-CTLA4
Monoclonal Antibody, in Patients with Refractory Metastatic Colorectoal Cancer
Ki Y. Chung, MD - Memorial Sloan-Kettering Cancer Center |
| 2:00 pm - 2:15 pm |
Immune-Related Adverse Events in Patients with Melanoma Treated with Tremelimumab (CP-675,206)
Dimitri Pavlov, PhD - Pfizer, Inc. |
| 2:15 pm - 2:30 pm |
EGFRVIII Vaccine (CDX-110) Alone and with Simultaneous
Temozolomide in Patients with Newly Diagnosed, Resected, EGFRVIII Positive GBM
John Sampson, MD, PhD - Duke University Medical Center |
| 2:30 pm - 3:00 pm |
Novel Agents in Renal Cell Carcinoma: Challenges and
Opportunities in Capitalizing on Active Therapy
Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center |
| 3:20 pm - 4:45 pm |
iSBTc Presidential Session
Chair: Jon M. Wigginton, MD - Merck & Co., Inc.
|
| 3:20 pm - 3:25 pm |
Introduction
Jon M. Wigginton, MD - Merck & Co., Inc. |
| 3:25 pm - 3:45 pm |
Apoptosis of Circulating Tumor-Antigen Specific TH1 CD4+ T Cells from Melanoma Patients
Amy K. Wesa, PhD - University of Pittsburgh School of Medicine |
| 3:45 pm - 4:05 pm |
Priming and Selection of Allorestricted, Peptide-Specific T Cells for Adoptive Therapy of Tumors
Susanne Wilde - Institute of Molecular Immunology |
| 4:05 pm - 4:25 pm |
Retrospective Analysis of Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma Who had Received Prior
Antiangiogenic Therapy
Talya Schwarzberg, MD - Beth Israel Deaconess Medical Center |
| 4:25 pm - 4:45 pm |
CD4+CD25highFoxp3+ T Regulatory Cells Kill Autologous CD8(+) and
CD4(+) T Cells Using GranzymeB and Fas/FasL-Mediated Pathways
Laura Strauss, PhD - San Raffaele Telethon Institute for Gene Therapy |
